Alectinib
- Generic Name
- Alectinib
- Brand Names
- Alecensa, Alecensaro
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N4O2
- CAS Number
- 1256580-46-7
- Unique Ingredient Identifier
- LIJ4CT1Z3Y
- Background
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...
- Indication
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...
- Associated Conditions
- Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03178552
- Locations
- 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
NCT Neuro Master Match - N²M² (NOA-20)
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 228
- Registration Number
- NCT03158389
- Locations
- 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT03155009
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Hopital Augustin Morvan; Oncologie Thoracique, Brest, France
🇫🇷Hopital Jean Minjoz; Pneumologie, Besancon, France
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03131206
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 187
- Registration Number
- NCT02838420
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Guangdong General Hospital, Guangzhou, China
🇨🇳Shanghai chest hospital, Shanghai, China
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT02621047
- Locations
- 🇸🇰
Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia
🇨🇿Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT02604342
- Locations
- 🇮🇹
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy
🇵🇱Medical University of Gdansk, Gdansk, Poland
🇮🇹Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT02521051
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
- Conditions
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 50
- Registration Number
- NCT02314481
- Locations
- 🇬🇧
Univeristy College London Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.